Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail)

v3.22.2.2
Research and Development Agreements - Schedule of Research and Development Revenue from Related Party Relates to Revenue from Research and Development Agreements (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue Recognition [Line Items]        
Total research and development revenue $ 4,240 $ 2,379 $ 17,143 $ 20,733
Millennium Pharmaceuticals, Inc.        
Revenue Recognition [Line Items]        
Total research and development revenue 0 0 2,586 13,136
Millennium Pharmaceuticals, Inc. | Takeda Development Agreement        
Revenue Recognition [Line Items]        
Total research and development revenue 0 0 0 13,114
Millennium Pharmaceuticals, Inc. | Takeda Multi Target Agreement        
Revenue Recognition [Line Items]        
Total research and development revenue $ 0 $ 0 $ 2,586 $ 22